What question did this study set out to answer?

To explore the outcomes of dual antiviral therapy in a patient with severe mpox and profound HIV-related immunosuppression.

March 18, 2026Open Access

Rapid viral clearance and clinical recovery with dual antiviral therapy in severe mpox with profound HIV-related immunosuppression : a case report

Key Points

To explore the outcomes of dual antiviral therapy in a patient with severe mpox and profound HIV-related immunosuppression.
Patient diagnosed with severe mpox and HIV infection.
Dual antiviral therapy initiated for treatment.
Clinical observations of rash and fever over four weeks.
Rapid viral clearance noted after initiating therapy.
Notable clinical recovery observed within a short time frame.
Continuous monitoring of CD4 counts and immunosuppression status.

Abstract

A 30-year-old man with CDC stage C HIV infection, initially diagnosed due to cerebral toxoplasmosis, and a 5-year history of CD4 counts <100/mm³ with poor adherence to antiretroviral therapy (ART), was admitted in France in 2025 with a four-week history of persistent fever and a disseminated rash. The rash had started on his lower back a month prior, then progressively involved palms, soles, oral cavity, and anal/genital mucosa. Treatment with oral amoxicillin had no effect on the lesions.

Rapid viral clearance and clinical recovery with dual antiviral therapy in severe mpox with profound HIV-related immunosuppression : a case report

Key Points

Abstract

Cite This Study